[go: up one dir, main page]

MX2023007012A - Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe). - Google Patents

Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe).

Info

Publication number
MX2023007012A
MX2023007012A MX2023007012A MX2023007012A MX2023007012A MX 2023007012 A MX2023007012 A MX 2023007012A MX 2023007012 A MX2023007012 A MX 2023007012A MX 2023007012 A MX2023007012 A MX 2023007012A MX 2023007012 A MX2023007012 A MX 2023007012A
Authority
MX
Mexico
Prior art keywords
methods
cardiovascular disease
metabolic disorders
subunit beta
inhbe
Prior art date
Application number
MX2023007012A
Other languages
English (en)
Inventor
Aris Baras
Manuel Allen Revez Ferreira
Luca Andrea Lotta
Parsa Akbari
Olukayode Sosina
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023007012A publication Critical patent/MX2023007012A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)

Abstract

La presente descripción proporciona métodos para tratar a un sujeto que padece trastornos metabólicos y/o enfermedades cardiovasculares, métodos de identificación de sujetos que tienen un mayor riesgo de desarrollar un trastorno metabólico y/o una enfermedad cardiovascular, y métodos de detección de moléculas de ácido nucleico variante de la subunidad beta E de inhibina humana y polipéptidos variantes.
MX2023007012A 2020-12-14 2021-12-13 Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe). MX2023007012A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063124949P 2020-12-14 2020-12-14
US202163159019P 2021-03-10 2021-03-10
US202163233258P 2021-08-14 2021-08-14
US202163274595P 2021-11-02 2021-11-02
PCT/US2021/063150 WO2022132666A1 (en) 2020-12-14 2021-12-13 Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors

Publications (1)

Publication Number Publication Date
MX2023007012A true MX2023007012A (es) 2023-06-27

Family

ID=79601970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007012A MX2023007012A (es) 2020-12-14 2021-12-13 Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe).

Country Status (9)

Country Link
US (4) US20220184114A1 (es)
EP (1) EP4259279A1 (es)
JP (1) JP2024501627A (es)
KR (1) KR20230119130A (es)
AU (1) AU2021400488A1 (es)
CA (1) CA3201466A1 (es)
IL (1) IL302783A (es)
MX (1) MX2023007012A (es)
WO (1) WO2022132666A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201466A1 (en) * 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
TW202421169A (zh) * 2021-07-21 2024-06-01 美商艾拉倫製藥股份有限公司 代謝疾患相關的標靶基因ｉＲＮＡ組成物及其使用方法
IL311454A (en) * 2021-09-20 2024-05-01 Alnylam Pharmaceuticals Inc Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
AU2024230877A1 (en) * 2023-03-02 2025-09-04 Tuojie Biotech (Shanghai) Co., Ltd. SIRNA TARGETING INHIBIN βE, SIRNA CONJUGATE, AND MEDICAL USE THEREOF
WO2024187190A2 (en) * 2023-03-09 2024-09-12 Basecure Therapeutics Llc Compositions and methods for inhibition of expression of inhibin subunit beta e (inhbe) genes
WO2025049773A1 (en) * 2023-08-30 2025-03-06 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use
WO2025082057A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 抑制抑制素Beta E基因表达的抑制剂及其用途
WO2025129029A2 (en) * 2023-12-14 2025-06-19 Tiziana Life Sciences Plc Combinations of foralumab with glucagon-like peptide 1 (glp-1) agonists or sodium-glucose cotransporter-2 (sglt2) inhibitors and methods of use thereof
WO2025131079A1 (en) * 2023-12-21 2025-06-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric inhbe
WO2025228441A2 (en) * 2024-04-30 2025-11-06 Sanegene Bio Usa Inc. Small interfering rna targeting inhbe and uses thereof
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion
CN120905229A (zh) * 2024-12-09 2025-11-07 成都先衍生物技术有限公司 一种靶向INHBE基因表达的siRNA及其缀合物和用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP1695978A1 (en) 1990-06-11 2006-08-30 Gilead Sciences, Inc. Nucleic acid ligands
US7507787B2 (en) 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
US20070134261A1 (en) 2001-12-03 2007-06-14 Hancock Robert E Effectors of innate immunity
US20070190533A1 (en) 2001-12-03 2007-08-16 Hancock Robert E Effectors of innate immunity
CN101215601A (zh) 2001-12-03 2008-07-09 英属哥伦比亚大学 先天免疫的效应物
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
CN101652481A (zh) 2007-02-02 2010-02-17 先锋高级育种国际公司 二倍体胚的选择性切除
WO2008112730A1 (en) 2007-03-14 2008-09-18 The Regents Of The University Of California A method for using lowstrength electric field network (lsen) and immunosuppressive strategies to mediate immune responses
US20100291580A1 (en) 2007-12-19 2010-11-18 Aderans Research Institute, Inc Biomarkers for trichogenicity
AU2009223115B2 (en) 2008-03-14 2015-09-24 Humanzyme, Inc. Recombinant production of authentic human proteins using human cell expression systems
US8137970B2 (en) 2008-06-30 2012-03-20 Ewha University-Industry Collaboration Foundation Methods for inducing the differentiation of hematopoietic stem cells into megakaryocytes and platelets, and gene controlling the differentiation
US20100144838A1 (en) 2008-12-01 2010-06-10 Beck William T Methods for Identifying Modulators of Pyrimidine Tract Binding Protein
US20120141603A1 (en) 2009-04-21 2012-06-07 British Columbia Cancer Agency Branch Methods and compositions for lung cancer prognosis
WO2011020014A1 (en) 2009-08-14 2011-02-17 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
WO2011053281A1 (en) 2009-10-27 2011-05-05 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
TR201903376T4 (tr) 2009-10-29 2019-04-22 Regeneron Pharma Çok fonksiyonlu alleller.
EP3260130B1 (en) * 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
US20130202564A1 (en) 2010-04-09 2013-08-08 University Of Southern California Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration
US20120258878A1 (en) 2010-08-04 2012-10-11 Med Biogene Inc. Prognostic gene signatures for non-small cell lung cancer
WO2012022634A1 (en) 2010-08-16 2012-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Classification, diagnosis and prognosis of multiple myeloma
WO2012074870A2 (en) 2010-11-29 2012-06-07 Mote Marine Laboratory, Inc. Fish sexual characteristic determination using peptide hormones
WO2012162660A2 (en) 2011-05-25 2012-11-29 Brown University Methods using dna methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies
US20140178348A1 (en) 2011-05-25 2014-06-26 The Regents Of The University Of California Methods using DNA methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies
US10024860B2 (en) 2012-03-28 2018-07-17 Massachusetts Institute Of Technology Cancer-related extracellular matrix signatures and related methods and products
US9526800B2 (en) 2012-03-28 2016-12-27 Massachusetts Institute Of Technology Cancer-related extracellular matrix signatures and related methods and products
SG11201503271XA (en) 2012-11-06 2015-05-28 Scholar Rock Inc Compositions and methods for modulating cell signaling
WO2014089121A2 (en) 2012-12-03 2014-06-12 Thomas Ichim Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases
US20140287948A1 (en) 2013-03-15 2014-09-25 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
CA2907120C (en) 2013-03-15 2023-10-17 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
CN105531378B (zh) 2013-09-12 2021-04-09 拉什大学医学中心 用于表征可动关节软组织损伤后细胞修复反应的转录组学指数
US20170182080A1 (en) 2014-03-14 2017-06-29 Bo Han Functional scaffold for tissue repair and regeneration
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
US20170306027A1 (en) * 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
WO2019010304A1 (en) 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation MICROPARTICLES COATED WITH MINERALS FOR GENES ADMINISTRATION IN CHRONIC WOUND THERAPY
US20200347359A1 (en) 2018-01-08 2020-11-05 The Regents Of The University Of Colorado, A Body Corporate 3D in vitro Models of Lung Tissue
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US20200147118A1 (en) * 2018-11-09 2020-05-14 Ottawa Heart Institute Research Corporation Compositions and methods for detection, risk assessment and treatment of diabetes, obesity, and inflammation
CN120519489A (zh) 2018-12-19 2025-08-22 维萨梅布有限公司 编码蛋白质的rna
EP3942048A1 (en) * 2019-03-20 2022-01-26 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors
MY198403A (en) 2019-06-12 2023-08-28 Cryocord Sdn Bhd Production of Therapeutics Potential Mesenchymal Stem Cells
JP2023501386A (ja) 2019-11-08 2023-01-18 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の治療
US20230193205A1 (en) 2020-04-19 2023-06-22 Figene, Llc Gene modified fibroblasts for therapeutic applications
CA3201466A1 (en) * 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors

Also Published As

Publication number Publication date
CA3201466A1 (en) 2022-06-23
US11759476B2 (en) 2023-09-19
AU2021400488A1 (en) 2023-06-22
KR20230119130A (ko) 2023-08-16
IL302783A (en) 2023-07-01
JP2024501627A (ja) 2024-01-15
US20230172963A1 (en) 2023-06-08
US20220313726A1 (en) 2022-10-06
US11957704B2 (en) 2024-04-16
US20220184114A1 (en) 2022-06-16
WO2022132666A1 (en) 2022-06-23
EP4259279A1 (en) 2023-10-18
US20240252528A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
MX2023007012A (es) Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe).
Halford et al. New astroglial injury-defined biomarkers for neurotrauma assessment
Becker-Haimes et al. Parent–youth informant disagreement: Implications for youth anxiety treatment
Abdallah et al. Glutamate metabolism in major depressive disorder
Martinez-Fernandez et al. Postoperative apathy can neutralise benefits in quality of life after subthalamic stimulation for Parkinson's disease
Chang et al. Impact of avolition and cognitive impairment on functional outcome in first-episode schizophrenia-spectrum disorder: a prospective one-year follow-up study
Di Battista et al. Altered blood biomarker profiles in athletes with a history of repetitive head impacts
Lupton et al. A prospective cohort study of prodromal Alzheimer’s disease: Prospective Imaging Study of Ageing: Genes, Brain and Behaviour (PISA)
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
BRPI0720035A2 (pt) métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
WO2020154268A3 (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
Glausier et al. Lower glutamic acid decarboxylase 65-kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophrenia
BR112016007630A2 (pt) análise e rastreamento de resultado clínico
Jutten et al. A neuropsychological perspective on defining cognitive impairment in the clinical study of Alzheimer’s disease: Towards a more continuous approach
Kranaster et al. Protein S-100 and neuron-specific enolase serum levels remain unaffected by electroconvulsive therapy in patients with depression
MX2022016458A (es) Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75).
Dede et al. Rapid eye movement sleep without atonia constitutes increased risk for neurodegenerative disorders
Almosnino et al. The role of hyperbaric oxygen as salvage therapy for sudden sensorineural hearing loss
GB0524110D0 (en) Biomarkers and methods for identification of agents useful in the treatment of affective disorders
Çıkrıkçılı et al. Non-convulsive status epilepticus associated with glutamic acid decarboxylase antibody
Paprocka et al. Melatonin and Angelman syndrome: implications and mathematical model of diurnal secretion
Müller et al. Hypomethylation in Parkinson’s disease: An epigenetic drug effect
Mills et al. Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients
Vassileva et al. Attitudes toward antipsychotic medication, insight and psychopathology in outpatients with schizophrenia
WO2020139830A3 (en) Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors